CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia
Mariela Sivina(The University of Texas MD Anderson Cancer Center), Jan A. Burger(The University of Texas MD Anderson Cancer Center), Laura Z. Rassenti(University of California San Diego), Michael J. Keating(The University of Texas MD Anderson Cancer Center), Diana Krupnik(The University of Texas MD Anderson Cancer Center), Andreas Rosenwald(Comprehensive Cancer Center Mainfranken), Lillian Werner(Dana-Farber Cancer Institute), Susan Lerner(Molecular Templates (United States)), Thomas J. Kipps(University of California San Diego), Xuelin Huang(The University of Texas MD Anderson Cancer Center), Elena Hartmann(University of Würzburg), Lianchun Xiao(The University of Texas MD Anderson Cancer Center), William G. Wierda(University of Maryland, Baltimore), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Donna Neuberg(Otsuka (Japan)), Ruth LaPushin(The University of Texas MD Anderson Cancer Center), Susan O’Brien(University of California, Irvine)
Cited by 126
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|10k
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k